In Friday’s Wall Street session, Pasithea Therapeutics Corp. (NASDAQ:KTTA) shares traded at $1.05, unchanged from the previous session.
As of this writing, 1 analysts cover Pasithea Therapeutics Corp. (NASDAQ:KTTA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $2.30 and a low of $2.30, we find $2.30. Given the previous closing price of $1.05, this indicates a potential upside of 119.05 percent. KTTA stock price is now -9.95% away from the 50-day moving average and -8.01% away from the 200-day moving average. The market capitalization of the company currently stands at $28.00M.
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $2.30 as their price target over the next twelve months.
In other news, Delaney David, Member of 10% owner group bought 1,000 shares of the company’s stock on Oct 17. The stock was bought for $1,110 at an average price of $1.11. Upon completion of the transaction, the Member of 10% owner group now directly owns 227,521 shares in the company, valued at $0.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 29, Member of 10% owner group Shahinian Eric bought 6,710 shares of the business’s stock. A total of $7,757 was incurred on buying the stock at an average price of $1.16. This leaves the insider owning 1,788,415 shares of the company worth $1.88 million. A total of 7.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KTTA stock. A new stake in Pasithea Therapeutics Corp. shares was purchased by STATE STREET CORP during the first quarter worth $25,000. GEODE CAPITAL MANAGEMENT, LLC invested $21,000 in shares of KTTA during the first quarter. In total, there are 12 active investors with 14.30% ownership of the company’s stock.
Friday morning saw Pasithea Therapeutics Corp. (NASDAQ: KTTA) opened at $1.0200. During the past 12 months, Pasithea Therapeutics Corp. has had a low of $0.81 and a high of $8.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 51.20, and a quick ratio of 51.20. The fifty day moving average price for KTTA is $1.1640 and a two-hundred day moving average price translates $1.1413 for the stock.
The latest earnings results from Pasithea Therapeutics Corp. (NASDAQ: KTTA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.07, missing analysts’ expectations of -$0.02 by -0.05. This compares to -$0.09 EPS in the same period last year.
Pasithea Therapeutics Corp.(KTTA) Company Profile
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.